News

Article

Avantor to Increase Global Capacity for Single-Use Technologies

Avantor plans to increase its single-use manufacturing footprint by 30% and double its cleanroom space in the US and Europe.

Avantor announced on April 26, 2021 that it is increasing its global capacity for high-quality single-use technologies used in the production of biologics and vaccines.

According to a company press release, Avantor plans to increase its single-use manufacturing footprint by 30% and double its cleanroom space in the US and Europe. The expansion will also support customer demand for monoclonal antibodies, cell and gene therapies for oncology and other diseases, and vaccines, including those for COVID-19.

"The industry's response to the COVID-19 pandemic has relied heavily on the integration of single-use products into biopharma production processes,” said Ger Brophy, executive vice-president of Biopharma Production at Avantor, in the press release. “Efficacy and safety are of the utmost importance to our customers, and they look to us to understand and support their requirements as they rapidly expand their own manufacturing capacity. These additions to our global single-use manufacturing ecosystem are critical steps in enabling our customers to get therapies to patients quickly.”

Source: Avantor

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content